Bloomberg News (12/1, Feeley) reported, Takeda Pharmaceutical Co. "may face as many as 10,000 lawsuits in US courts over allegations that its Actos [pioglitazone] diabetes drug causes bladder cancer, and a group of judges is preparing to decide where they should be consolidated." Several months ago, "US regulators found...that an analysis of a company-sponsored study showed some users of Actos, the world's best-selling diabetes medication, faced an increased risk of developing the potentially fatal disease." Bloomberg News adds that lawyers representing claimants assert that "The evidence linking Actos to bladder cancer "is unusually strong and clear."